Search Results
Your search for The ASCO Post Staff,The ASCO Post Staff matches 6792 pages
Showing 151 - 200
David Allen Barbie, MD, on Clinical and Molecular Features of Participants in the ADRIATIC Trial
David Allen Barbie, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews specific clinical and molecular features of early progressors and long-term progression-free survivors from the phase III ADRIATIC trial, which assessed consolidation durvalumab vs placebo...
ASCO 2025: Switching to Camizestrant After Detection of an ESR1 Mutation Improves Progression-Free Survival for Some Patients With Advanced Breast Cancer
Switching to treatment with camizestrant if an ESR1 mutation is detected during first-line treatment can help slow cancer growth for patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, according to findings from the phase III SERENA-6 clinical trial. The research is...
ASCO 2025: Perioperative Durvalumab Boosts FLOT Chemotherapy Benefit for Patients With Gastric Cancers
Results from an international phase III clinical trial found that treating patients with stage II, III, and IVA resectable gastric cancer and gastroesophageal junction (GEJ) cancer with perioperative durvalumab and FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) helped...
Andrew J. Armstrong, MD, MS, on ARCHES: 5-Year Overall Survival Follow-up
Andrew J. Armstrong, MD, MS, of Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, discusses the 5-year overall survival analysis of the ARCHES trial, which investigated enzalutamide plus androgen-deprivation therapy in patients with metastatic...
Clifford A. Hudis, MD, FASCO, FACP, on ASCO Guidelines Assistant
Clifford A. Hudis, MD, FASCO, FACP, Chief Executive Officer of ASCO, discusses ASCO Guidelines Assistant, an AI-based collaboration between ASCO and Google Cloud which draws from ASCO’s evidence-based, published clinical practice guidelines, offering clinicians ready access to timely, trustworthy...
Heinz-Josef Lenz, MD, on MSI-H/dMMR Metastatic Colorectal Cancer: Expanded Analyses From CheckMate 8HW
Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, reviews analyses from the CheckMate 8HW trial, which evaluated nivolumab plus ipilimumab vs chemotherapy or nivolumab monotherapy for microsatellite instability–high/mismatch repair–deficient...
Mazyar Shadman, MD, PhD, on Doublet for Treatment-Naive CLL/SLL
Mazyar Shadman, MD, PhD, of Fred Hutchinson Cancer Center and the University of Washington, presents results from arm D of the SEQUOIA trial, which evaluated the combination of zanubrutinib and venetoclax in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma...
Yelena Y. Janjigian, MD, on Gastric/GEJ Cancer: Immunotherapy Plus FLOT
Yelena Y. Janjigian, MD, of Memorial Sloan Kettering Cancer Center, presents event-free survival data from the phase III MATTERHORN trial of the PD-L1 inhibitor durvalumab plus FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy) in patients with resectable gastric or...
Raffaele Califano, MD, on EGFR-Mutant Advanced NSCLC: MARIPOSA-2
Raffaele Califano, MD, of the Christie NHS Foundation Trust and the University of Manchester, discusses outcomes by osimertinib resistance mechanisms in MARIPOSA-2, a study that evaluated the efficacy of the bispecific antibody amivantamab-vmjw plus chemotherapy vs chemotherapy in patients with...
ASCO 2025: Adding Nivolumab to Adjuvant Chemoradiotherapy Reduces Risk of Recurrence in Locally Advanced Head and Neck Cancer
Adding nivolumab to chemoradiotherapy after surgery can decrease the chance of recurrence in patients with locally advanced head and neck squamous cell carcinoma, according to findings from the international phase III NIVOPOSTOP trial. This study is one of the first to show an improvement in the...
ASCO 2025: Adding Atezolizumab to Adjuvant Chemotherapy Improves Disease-Free Survival in dMMR Colon Cancer
Results from the international phase III ATOMIC study demonstrated that patients with deficient mismatch repair (dMMR) colon cancer who receive atezolizumab in addition to adjuvant chemotherapy experience a 50% reduction in disease recurrence or death compared with chemotherapy alone. The findings...
Nicholas C. Turner, MD, PhD, on Treating Emergent ESR1 Mutations in Advanced Breast Cancer
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents findings from the phase III, double-blind ctDNA-guided SERENA-6 trial, which evaluated the combination of camizestrant plus a CDK4/6 inhibitor to treat emergent ESR1 mutations during first-line endocrine therapy for patients with...
Stuart J. Wong, MD, on Adjuvant Regimen in Resected HNSCC
Stuart J. Wong, MD, of the Medical College of Wisconsin and Plenary discussant, reviews findings from the phase III NIVOPOSTOP randomized trial, which investigated the adjuvant use of nivolumab added to radiochemotherapy for patients with resected head and neck squamous cell carcinoma who are at...
Andrew Kuykendall, MD, on Hepcidin Mimetic for Polycythemia Vera
Andrew Kuykendall, MD, of Moffitt Cancer Center, discusses findings from the phase III VERIFY trial, which compared the efficacy of rusfertide vs placebo in patients with polycythemia vera who continue their current standard of care therapy (Abstract LBA3).
Christopher M. Booth, MD, on a Structured Exercise Program for Patients With Colon Cancer
Christopher M. Booth, MD, of Queen’s University, reviews findings from the randomized phase III Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE) trial, which evaluated the impact of a structured exercise program on disease-free survival in patients with stage III or high-risk stage II colon...
Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, on CLL/SLL: First-Line Zanubrutinib Monotherapy in Patients With del(17p)
Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, of Alfred Hospital and Monash University, reviews results from the 5-year follow-up of arm C of the SEQUOIA trial of treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7011).
Nicholas C. Turner, MD, PhD, on INAVO120: Final Overall Survival Analysis
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents final overall survival data from the INAVO120 trial of inavolisib/placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer (Abstract 1003).
Giuseppe Curigliano, MD, PhD, on Patient-Reported Outcomes From EMBER-3
Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, IRCCS, University of Milano, discusses patient-reported outcomes from the phase III EMBER-3 trial, which investigated treatment with imlunestrant, investigator’s choice of standard endocrine therapy, or imlunestrant plus abemaciclib in ...
William G. Wierda, MD, PhD, on Lisocabtagene Maraleucel in Relapsed/Refractory CLL: TRANSCEND CLL 004
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses two abstracts on lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In Abstract 7037, liso-cel with ibrutinib demonstrated...
William G. Wierda, MD, PhD, on Fixed-Duration Ibrutinib and Venetoclax in First-Line CLL
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, reviews the final analysis of phase II CAPTIVATE study demonstrating the long-term efficacy and safety of ibrutinib plus venetoclax for previously untreated patients with chronic lymphocytic leukemia/small lymphocytic ...
Sacituzumab Govitecan and Pembrolizumab Improve Disease Control in Advanced PD-L1–Positive Triple-Negative Breast Cancer
Results from an international phase III clinical trial show that treatment with sacituzumab govitecan-hziy and pembrolizumab helps patients with unresectable, locally advanced or metastatic PD-L1–positive triple-negative breast cancer live longer without disease progression compared with...
Trastuzumab Deruxtecan Improves Survival Outcomes in Patients With HER2-Positive Gastric/GEJ Cancer in Second-Line Setting
The international phase III DESTINY-Gastric04 clinical trial found that second-line treatment with fam-trastuzumab deruxtecan-nxki can help people with advanced HER2-positive gastric cancers that have grown during first-line treatment live about 3 months longer. These findings further support the...
Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy
Results from an international clinical trial show that a 14-gene molecular assay can help identify patients with early-stage nonsquamous non–small cell lung cancer (NSCLC) who could benefit from adjuvant chemotherapy after surgery. The research will be presented at the 2025 ASCO Annual Meeting...
Vepdegestrant Improves Progression-Free Survival in Select Patients With ESR1-Mutant Advanced Breast Cancer
Results from VERITAC-2 trial showed that the proteolysis-targeting chimera (PROTAC) vepdegestrant could extend progression-free survival for people with previously treated estrogen receptor (ER)-positive, HER2-negative advanced breast cancer with an ESR1 mutation. The research will be presented at...
Encorafenib/Cetuximab Plus Chemotherapy Improves Survival in BRAF V600E–Mutant Metastatic Colorectal Cancer
Results from an international phase III study showed that the targeted therapy combination of encorafenib and cetuximab with mFOLFOX6 (leucovorin, fluorouracil, and oxaliplatin) chemotherapy may help patients with BRAF V600E–mutant metastatic colorectal cancer live longer. After early results from...
ASCO 2025: Alcohol-Related Cancer Deaths Are on the Rise in the United States
A new study led by experts at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, is the first to look at trends over time in alcohol-linked cancer mortality across the United States. The findings were presented at the 2025 ASCO Annual Meeting (Abstract ...
ASCO 2025: Impact of Wildfire-Related Pollution on Survival in NSCLC
Inhaling wildfire-related air pollution may reduce the likelihood of survival among patients with non–small cell lung cancer (NSCLC), according to new findings presented by Singhal et al at the 2025 ASCO Annual Meeting (Abstract 10520). Background Wildfire-related air pollution contains particulate ...
Subset of Men With Rare Prostate Cancer May Benefit From Immunotherapy Added to Chemotherapy and Targeted Maintenance Therapy
Treatment options for aggressive-variant prostate cancer are limited, but a subset of patients have had promising long-term responses with a combination of carboplatin plus cabazitaxel chemotherapy, followed by PARP inhibitor maintenance. This novel combination treatment approach was the focus of a ...
Spatial Transcriptomics Identifies Novel Subtypes Associated With Disease Prognosis in Leiomyosarcoma
Patients with leiomyosarcoma experience a high risk of recurrence and have limited treatment options. No biomarkers or targetable mutations currently improve diagnosis, prognosis, or treatment. Spatial transcriptomics, which are rarely used in sarcomas, may provide insights into leiomyosarcoma...
Study Finds Novel Triplet Regimen Safe and Effective for Patients With Higher-Risk MDS and CMML
Patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) often experience temporary responses to current treatments, such as hypomethylating agents, which leads to an increased risk of the disease evolving to acute myeloid leukemia. In a phase II study,...
CAR T-Cell Therapy Continues to Demonstrate Activity in Advanced Clear Cell Renal Cell Carcinoma
For patients with metastatic clear cell renal cell carcinoma who did not benefit from checkpoint and tyrosine kinase inhibitors, limited alternative treatment options are available. ALLO-316 is a novel chimeric antigen receptor (CAR) T-cell therapy designed to recognize and kill cells expressing...
Online Genetic Testing Platform Demonstrates Notable Engagement Among Patients With Young-Onset Colorectal Cancer
Universal germline testing is essential for identifying hereditary cancer risk, especially for patients with young-onset colorectal cancer who were diagnosed before the age of 50. However, the implementation of universal germline testing has been hampered by increasing demand and limited physician...
Genomic Score May Predict Progression From Precursor Condition to Active Multiple Myeloma
Investigators have developed a genomic score, called multiple myeloma-like (MM-like), for predicting progression from multiple myeloma precursor conditions to active cancer, study results published in Nature Genetics showed. The researchers created a map of the genome of multiple myeloma and its...
Climate Change and Risk for Breast and Gynecologic Cancers
Climate change may be contributing to a small but notable increase in the incidence and mortality rates of breast, ovarian, endometrial, and cervical cancers in the Middle East and North Africa, according to a recent study published by Mataria and Chun in Frontiers in Public Health. Background...
Physical Function Acts as Predictor of Survival for Daratumumab-Based Therapy in Multiple Myeloma
Patients with multiple myeloma who had lower physical function scores at the time of treatment initiation demonstrated a greater benefit to daratumumab treatment than those with higher physical function scores, according to the results of a study published in the European Journal of Haematology....
Alcohol May Be Linked to Higher Risk of Pancreatic Cancer
Investigators may have uncovered a modest but potentially significant association between alcohol consumption and the risk of developing pancreatic cancer, according to a recent study published by Naudin et al in PLOS Medicine. Background Pancreatic cancer is the twelfth most common cancer type...
ESMO Releases Version 2.0 of the Magnitude of Clinical Benefit Scale
The European Society for Medical Oncology (ESMO) has announced the publication of the latest version of its scale that measures the clinical benefit of cancer treatments, the ESMO-MCBS (ESMO-Magnitude of Clinical Benefit Scale). The ESMO-MCBS was first introduced in 2015 and updated to version 1.1...
DOJ Finds Federal Bureau of Prisons’ Colorectal Cancer Screening Practices Lacking
An evaluation by the Department of Justice Office of the Inspector General (DOJ OIG) of the Federal Bureau of Prisons’ (BOP) colorectal cancer screening practices for inmates and their clinical follow-up for positive screenings found several serious operational and managerial deficiencies...
Use of Niraparib in Patients With Advanced Melanoma
Researchers may have uncovered early indications of the clinical benefit of niraparib in patients with advanced melanoma whose tumors have specific genetic changes impacting DNA repair, according to a recent study published by Kim et al in JCO Precision Oncology. Background The U.S. Food and Drug...
W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of OSUCCC-James
Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J....
Fellows of the AACR Academy Class of 2025
Listed here is the newly elected 2025 class of Fellows of the American Academy for Cancer Research (AACR) Academy, which was recognized at the AACR Annual Meeting, April 25–30, 2025, in Chicago. Rafi Ahmed, PhD, Atlanta, Georgia Sir Shankar Balasubramanian, PhD, Cambridge, UK Bradley Bernstein, MD, ...
The Power of Translational Science to Transform the Lives of Patients Worldwide
Despite a 30-year history as an ASCO volunteer, for Eric J. Small, MD, FASCO, this past year as President-Elect has opened new perspectives on the organization he will soon lead as ASCO’s 62nd President, effective during the 2025 ASCO Annual Meeting, May 30–June 3, 2025, in Chicago. After serving...
Inavolisib-Based Regimen in PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
New findings from the phase III INAVO120 trial showed that adding inavolisib to palbociclib and fulvestrant may help extend survival and delay the time until treatment with chemotherapy in previously treated patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. The...
Extensive-Stage SCLC: Lurbinectedin and Atezolizumab
Results from a global phase III clinical trial found that maintenance therapy with a combination of the alkylating agent lurbinectedin and the PD-L1 inhibitor atezolizumab improved survival in some patients with extensive-stage small cell lung cancer (SCLC) compared with maintenance therapy with...
WGS Liquid Biopsies for HPV-Associated Head and Neck Squamous Cell Carcinoma
Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) detection of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), termed HPV-DeepSeek by the study investigators, showed greater sensitivity, specificity, and diagnostic accuracy than any current...
Abbreviated MRI Scans in Detecting Breast Cancer for Women With Dense Breasts
Abbreviated breast MRI scans demonstrated comparable diagnostic accuracy to full multiparametric protocol MRI scans for women with extremely dense breasts, according to findings from the DENSE trial published in Radiology. MRI scans have greater diagnostic accuracy than mammograms for women with...
Revealing Critical Insights for Precision Medicine in Patients With Metastatic Prostate Cancer
Investigators may have uncovered key differences in tumor biology but similarities in survival outcomes in instances of equal access to care between non-Hispanic Black and non-Hispanic White men with metastatic prostate cancer, according to a recent study published by Valle et al in JAMA Network...
Breast Cancer: Genome-Wide Study Identifies Two New Risk Genes in Black South African Women
Investigators have identified two genetic risk loci that may be associated with an increased risk of breast cancer for Black South African women, according to findings from a genome-wide association study published in Nature Communications. The two risk loci were between UNC13C and RAB27A on...
A High Proportion of U.S. Adults Are Behind on Cancer Screenings
Investigators have found that a large proportion of U.S. adults are behind on their cancer screenings, according to a new survey from the American Cancer Society Cancer Action Network (ACS CAN). Survey Methods and Findings In the Survivor Views Special Report: National Screening Survey,...
Gabapentin May Extend Survival in Patients With Glioblastoma
Investigators have found that the antiseizure/pain drug gabapentin may be associated with improved survival in patients with glioblastoma, according to a recent study published by Bernstock et al in Nature Communications. Background With about 12,000 new cases diagnosed annually in the United...
